Annual Report

Overview

The report covers Zelluna's 2024 transformation from Ultimovacs to a company focused on TCR-NK cell therapies for solid cancers. It highlights negative results from three UV1 Phase II trials, the wrap-up of that program, and the March 2025 business combination. Sustainability disclosures cover Board-led ESG governance, 12 year-end employees, operational Scope 1 and 2 emissions, estimated water consumption, waste, human-rights due diligence and zero whistle-blower incidents.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Publication date: 1 April 2025
Language: English
Pages
File size

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services